News
PTCT
48.04
+1.44%
0.68
Morgan Stanley Maintains Equal-Weight on PTC Therapeutics, Raises Price Target to $50
Benzinga · 2d ago
Novartis drops plans to develop Huntington’s disease candidate
Seeking Alpha · 2d ago
Insider Sell: Ptc Therapeutics
Insider Sell: Ptc Therapeutics
MT Newswires · 2d ago
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and PTC Therapeutics (PTCT)
TipRanks · 5d ago
PTC Therapeutics: Overdependence On One Asset, Poor Cash Management
Seeking Alpha · 6d ago
ClearPoint Neuro Is A 'Buy' Based On Growing Revenues And Decreasing Cash Burn
Seeking Alpha · 6d ago
Diving Into Design Therapeutics
Seeking Alpha · 01/29 04:59
Diving Into Dyne Therapeutics
Seeking Alpha · 01/19 22:01
BRIEF-Nice Recommends Reimbursement For Translarna
Reuters · 01/19 13:09
Vir Biotechnology: High Potential Returns With High Volatility Risks
Seeking Alpha · 01/19 07:59
RBC Capital Sticks to Its Hold Rating for PTC Therapeutics (PTCT)
TipRanks · 01/17 01:46
--RBC Boosts Price Target on PTC Therapeutics to $44 From $42, Maintains Sector Perform Rating
--RBC Boosts Price Target on PTC Therapeutics to $44 From $42, Maintains Sector Perform Rating
MT Newswires · 01/13 08:14
Credit Suisse Maintains Neutral on PTC Therapeutics, Raises Price Target to $48
Benzinga · 01/10 13:04
Credit Suisse Raises PTC Therapeutics' Price Target to $48 From $47, Keeps Neutral Rating
Credit Suisse Raises PTC Therapeutics' Price Target to $48 From $47, Keeps Neutral Rating
MT Newswires · 01/10 08:06
BRIEF-Ptc Therapeutics Provides An Update On Commercial Progress And Research And Development Pipeline At 41St Annual J.P. Morgan Healthcare Conference
Reuters · 01/09 14:19
PTC Therapeutics Sees Over 30% Revenue Growth In 2022; Shares Rise
PTC Therapeutics Sees Over 30% Revenue Growth In 2022; Shares Rise
MT Newswires · 01/09 11:25
RBC Capital Sticks to Their Hold Rating for PTC Therapeutics (PTCT)
TipRanks · 01/07 01:46
BRIEF-PTC Therapeutics Files For Shelf Of Up To 1.1 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
Reuters · 12/16/2022 22:04
Expert Ratings for PTC Therapeutics
Benzinga · 12/14/2022 21:03
More
Webull provides a variety of real-time PTCT stock news. You can receive the latest news about Ptc Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About PTCT
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).